Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Trending on Bing
Ex-KY officer found guilty
US added just 12,000 jobs
How to vote
'L.A. Law' actor dies
Body to be flown back to UK
To close 140 restaurants
MrBeast probe findings
Shark severs surfer’s leg
Peanut the squirrel seized
Louisiana helicopter crash
UN approves Indigenous body
Fire closes Ohio River bridge
Pilot error in F-35 crash
Soldier charged with murder
Iran threatens Israel, US
ACA enrollment opens
AP election reporting
Warhol artworks stolen
Orlando mass shooting
WA activates National Guard
PA ballot case ruling
World Series celebration
Performers announced
School book bans report
$425M military aid to UKR
US bolsters Middle East
Adams returns to court
TX citizenship status law
Files for bankruptcy
Glenn wins Grand Prix title
To vote on new contract
Gaza resumes polio shots
FBI warns of fake videos
Announces MLB retirement
FL prisoners file lawsuit
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly Stock Tumbles
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from widespread shortages in the U.
Eli Lilly Stock Tumbles After Disappointing Obesity Drug Sales
Eli Lilly shares slid after the drugmaker reported disappointing quarterly results, with sales of its popular diabetes and anti-obesity drugs lower than expected. Lilly said inventory decreases by wholesale distributors hurt sales of its diabetes drug Mounjaro and anti-obesity medicine Zepbound.
Eli Lilly's rare sales miss for weight-loss drug sends shares tumbling
Eli Lilly's high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies sat in warehouses, a 180-degree turn for the company after long struggling to meet outsized demand.
3d
Ozempic, Wegovy move closer to no longer being in shortage, FDA says
Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication ...
10d
on MSN
FDA says this weight loss drug shortage is over, but patients worry about cost and availability
Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.
3d
on MSN
Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
5d
on MSN
What You Need To Know Ahead of Eli Lilly's Earnings Wednesday
Eli Lilly will report third-quarter earnings Wednesday morning. Investor focus remains on the production and sales of its ...
The American Journal of Managed Care
1d
5 Essential Drugs Currently Facing Shortages
US drug shortages have decreased from 323 to 277 as of September 2024, yet many essential drugs remain scarce, with 50% of ...
3d
on MSN
Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says
It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...
3d
What You May Have Missed From Eli Lilly's Q3 2024 Earnings Disappointment
LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...
11d
Shady drugmaker used code words to sell knockoff weight-loss drug: Lawsuit
Amid ongoing legal battles over coveted GLP-1 therapies, a drug vendor in Washington state is accused of running an ...
WTTV
3d
Eli Lilly’s third quarter earnings miss and forecast cut lead to sharp stock drop
Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...
3d
on MSN
Hims & Hers stock falls 14% after FDA changes semaglutide supply status (update)
Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback